Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Category list : All-Wales Medicines Strategy Group

Sort by: Newest first Oldest first A-Z Z-A

  • The National Assembly for Wales building

    Restrictions on prescribing OTC treatments rejected in Wales Subscription

    24 APR 2019 14:16 By Corrinne Burns

    Proposals to restrict the prescribing of medicines and other treatments that are available over the counter will not go ahead in Wales.

  • Pre-exposure prophylaxis pills against HIV infection

    Three-year PrEP pilot begins in Wales

    17 JUL 2017 15:44

    A trial has begun in Wales to assess the use of the antiretroviral combination treatment emtricitabine/tenofovir disoproxil (marketed as Truvada) for pre-exposure prophylaxis (PrEP) against HIV infection.

  • vaughan gething wales welsh wales health secretary

    Treatment fund launched in Wales for newly approved drugs

    11 JAN 2017 17:31 By Debbie Andalo

    An £80m new treatment fund to pay for high-cost drugs approved for use on the NHS in Wales has been launched.

  • The Welsh Government office at Llandudno Junction

    Welsh audit body recommends managing medicines plan

    22 DEC 2016 9:10 By Gareth Malson

    The government, the NHS and health bodies should revise the indicators used to compare how different prescribers and organisations use medicines, says a report by the Welsh Audit Office.

  • Vaughan Getting, speaking at the RPS conference

    Gething confirms £80m fund for high-cost medicines in Wales

    19 JUL 2016 16:03

    A central fund worth £80m that will pay for the immediate use of new, high-cost medicines that are approved for use in Wales has been announced by Vaughan Gething, cabinet secretary for health for the Welsh government.

  • Carwyn Jones, First Minister of the National Welsh Assembly

    Welsh Labour pledge to create £80m central fund for high cost drugs Subscription

    15 APR 2016 10:11

    Welsh Labour has pledged to create an £80m central fund to pay for high cost medicines if they retain control of the National Assembly for Wales following the election on 5 May 2016.

  • January 2016: AWMSG approvals Subscription

    18 JAN 2016 13:51

    The All Wales Medicines Strategy Group (AWMSG) has approved the following medicines for use by the NHS in Wales: atazanavir/cobicistat (Evotaz) for adults infected with human immunodeficiency virus-1 (HIV-1); efavirenz (Sustiva) for children aged between 3 months and 3 years who are infected with HIV-1; macitentan (Opsumit) for adults with pulmonary arterial hypertension (only where the approved patient access scheme is used); empagliflozin (Jardiance) for type 2 diabetes. Full details ...

  • December 2015: AWMSG approvals Subscription

    11 JAN 2016 9:44

    The All Wales Medicines Strategy Group (AWMSG) has approved the following medicines for use in NHS Wales: Cetuximab (Erbitux; Merck Serono) for the first-line treatment of epidermal growth factor receptor-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan-based chemotherapy or the chemotherapy regimen FOLFOX. Ivacaftor (Kalydeco; Vertex) for cystic fibrosis (CF) in patients aged 6 years and older who have mutations in the CF transmembrane ...

  • December 2015: AWSMG approvals Subscription

    5 JAN 2016 16:18

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Abasaglar (a biosimilar of insulin glargine; Eli Lilly and Company) for diabetes mellitus in patients aged 2 years and above. Sucroferric oxyhydroxide (Velphoro; Vifor Fresenius Medical Care Renal Pharma) for controlling serum phosphorus levels in adults with chronic kidney disease who are on haemodialysis or peritoneal dialysis where non-calcium based ...

  • AWMSG November medicines approvals Subscription

    20 NOV 2015 16:22

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Xultophy (insulin degludec and liraglutide) for use with oral antidiabetic drugs to treat adults with type 2 diabetes — it can only be used when oral treatments combined with basal insulin do not provide adequate glycaemic control; Fomicyt (fosfomycin) to treat acute osteomyelitis, complicated urinary tract infections, nosocomial lower respiratory tract infections or bacterial ...

  • August 2015: AWMSG approvals Subscription

    8 SEP 2015 11:07

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): brimonidine gel for treating the symptoms of moderate-to-severe, persistent facial erythema associated with rosacea; Rezolsta (darunavir and cobicistat) for use in combination with other antiretroviral medicines to treat human immunodeficiency virus-1 infection in adults; magnesium aspartate dihydrate for treating and preventing magnesium deficiency in patients aged two ...

  • AWMSG medicines approvals Subscription

    27 JUL 2015 9:53

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Darunavir, in combination with other antiretrovirals, for treating human immunodeficiency virus-1 infection in children aged at least three years and weighing 15kg and over; peginterferon beta-1a for treating adults with relapsing-remitting multiple sclerosis; regorafenib for treating adults with unresectable or metastatic gastrointestinal stromal tumours who progressed ...

  • July 2015: AWMSG approvals Subscription

    10 JUL 2015 13:04

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Fostair (beclometasone/formoterol; Chiesi) inhaler for patients with chronic obstructive pulmonary disease, and Adcetris (brentuximab; Takeda) for adults with relapsed or refractory CD30+ Hodgkin lymphoma who have undergone an autologous stem cell transplant or following at least two other therapies. The drug is not recommended for treating systemic anaplastic large cell ...

  • June 2015 AWMSG approvals Subscription

    15 JUN 2015 14:54

    Adalimumab (Humira; AbbVie) can be prescribed in NHS Wales to treat active, enthesitis-related arthritis in patients aged six years and older, following its use being approved by the All Wales Medicines Strategy Group (AWMSG). The group has not recommended dapagliflozin (Forxgia; Bristol-Myers Squibb) as monotherapy for type 2 diabetes or aflibercept (Zaltrap; Sanofi) for metastatic colorectal cancer (in combination with irinotecan, ...

  • AWMSG medicines approvals Subscription

    27 MAY 2015 13:40

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): bedaquiline for pulmonary multidrug‑resistant tuberculosis in adult patients as part of an appropriate combination regimen; daclatasvir for chronic hepatitis C virus infection in adults with significant fibrosis or compensated cirrhosis (as part of combination treatment); defibrotide for severe hepatic veno-occlusive disease alongside haematopoietic stem-cell transplantation ...

  • AWMSG medicines approvals Subscription

    13 MAR 2015 16:46

    Infliximab biosimilars Inflectra (Hospira) and Remsima (Celltrion) have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG). Both can be used for any licensed indication in accordance with AWMSG or National Institute for Health and Care Excellence guidance and should be prescribed by brand. The group has also approved lurasidone (Latuda; Sunovion) to treat adults with schizophrenia and Anoro Ellipta (umeclidinium and vilanterol; GlaxoSmithKline) to relieve ...

  • Cabozantinib and follitropin alfa recommended in Wales Subscription

    6 FEB 2015 9:35

    Cabozantinib has been recommended for use by the All Wales Medicines Strategy Group for progressive, unresectable, locally advanced or metastatic medullary thyroid carcinoma. The group has also approved follitropin alfa for use in NHS Wales to stimulate follicular development in women: With anovulation unresponsive to clomiphene Undergoing superovulation for assisted reproduction With severe luteinising hormone and follicle-stimulating hormone deficiency It ...

  • AWMSG medicines decisions Subscription

    16 JAN 2015 11:12

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG) in January 2015: leuprorelin acetate as neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer; umeclidinium (Incruse) and olodaterol (Striverdi Respimat) to relieve symptoms in chronic obstructive pulmonary disease; ponatinib to treat chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia, ...

  • Alogliptin approved for use in Wales Subscription

    6 NOV 2014 17:11

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): alogliptin, in combination with metformin or a sulphonylurea, to treat adults with type 2 diabetes (Vipdomet — a combination tablet containing metformin and alogliptin — is also approved); bortezomib, with dexamethasone, to treat adults with progressive multiple myeloma who have received at least one previous treatment and for whom haematopoietic stem ...

  • AWMSG decisions Subscription

    2 OCT 2014 12:12

    The following medicines have not been recommended for use by the All Wales Medicines Strategy Group (AWMSG) and should not be prescribed in NHS Wales: Abiraterone (Zytiga) with prednisolone for metastatic castration-resistant prostate cancer in men who are asymptomatic or mildly symptomatic after androgen deprivation therapy (the drug is allowed for patients whose disease has progressed — as per National Institute ...

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.